ReviewFrontiers in medicine2023
Melanocyte-keratinocyte cross-talk in vitiligo.
Review in Frontiers in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 24 citations in OpenAlex.
- Markers of Systemic Metabolic Dysfunction in Vitiligo and Their Potential Role in Disease Pathogenesis: A Narrative Review.Health science reports · 2026Article
- Immune-mediated remodelling of tissue architecture in Post-Kala-Azar Dermal Leishmaniasis (PKDL).PLoS neglected tropical diseases · 2026Article
- Pharmacological Mechanisms of Active Constituents from Traditional Chinese Medicine for Vitiligo Treatment.Pharmaceuticals (Basel, Switzerland) · 2026Review
- The CREM-IL-15 axis: decoding the persistence-exhaustion paradox in NK cell immunotherapy.Cancer immunology, immunotherapy : CII · 2026Review
- Mechanistic Insights into Phytocompounds for Vitiligo Therapy: Current Evidence and Future Opportunities.Antioxidants (Basel, Switzerland) · 2026Review
- Mitochondrial DNA release via VDAC1 in keratinocytes: a key driver of innate immunity and vitiligo pathogenesis.Cell death & disease · 2026Article
- Hydroxypropyl-β-cyclodextrin co-delivery hydrogel of crisaborole and curcumin for combinational antioxidant/anti-inflammatory therapy of vitiligo.Materials today. Bio · 2026Article
- Exploring the Role of Radix Polygalae in Melanogenesis Related to Vitiligo: A Network Pharmacology Analysis with in vitro Validation.Clinical, cosmetic and investigational dermatology · 2026Article
- Gut and skin microbiome-metabolome pathways in vitiligo: from dysbiosis to immune activation and melanocyte dysfunction.Frontiers in immunology · 2026Review
- Human umbilical cord mesenchymal stem cell delivery of mitochondria to melanocytes enhances skin repigmentation efficacy in autologous epidermal cell suspension transplantation through the TNFAIP2-TNT system.International journal of biological sciences · 2026Article
- Unveiling a ceRNA Network Involving IL-8 and TNF-α in Active Generalized Vitiligo by Multi-Omics Integration.ImmunoTargets and therapy · 2026Article
- Sonotherapy Using Folic Acid-Ag-Bi2O3 Nanocomposites in 2D and 3D Cultural C540 Melanoma Cells.Journal of biomedical physics & engineering · 2025Article
- Shared Immunopathogenic Mechanisms in Chronic Spontaneous Urticaria, Vitiligo, and Hashimoto's Thyroiditis: The Role of Oxidative Stress and Vitamin D.Life (Basel, Switzerland) · 2025Review
- Exosomal miR-493-3p Promote the Secretion of CXCL10 by Suppressing Keratinocyte Autophagy in Vitiligo.Clinical, cosmetic and investigational dermatology · 2025Article
- Mechanistic Insights into the Stimulatory Effect of Melanogenesis of 4-Methylcoumarin Derivatives in B16F10 Melanoma Cells.International journal of molecular sciences · 2024Article
- CGF therapy: bridging androgenetic alopecia observations to psoriasis treatment via IL-17 pathway.Stem cell research & therapy · 2024Article
- The Anti-Vitiligo Effects of Feshurin In Vitro fromPharmaceuticals (Basel, Switzerland) · 2024Article
- Epidermal stem cells: skin surveillance and clinical perspective.Journal of translational medicine · 2024Review
- Changes in epidermal thickness and their correlation with clinical characteristics in patients with vitiligo.Archives of dermatological research · 2024Article
- The role of serum inflammatory factors in predicting treatment response in patients with vitiligo and concomitant Hashimoto's thyroiditis.Postepy dermatologii i alergologii · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 2 countries.
Funding
Abstract
Vitiligo is a common acquired pigmentary disorder that presents as progressive loss of melanocytes from the skin. Epidermal melanocytes and keratinocytes are in close proximity to each other, forming a functional and structural unit where keratinocytes play a pivotal role in supporting melanocyte homeostasis and melanogenesis. This intimate relationship suggests that keratinocytes might contribute to ongoing melanocyte loss and subsequent depigmentation. In fact, keratinocyte dysfunction is a documented phenomenon in vitiligo. Keratinocyte apoptosis can deprive melanocytes from growth factors including stem cell factor (SCF) and other melanogenic stimulating factors which are essential for melanocyte function. Additionally, keratinocytes control the mobility/stability phases of melanocytes via matrix metalloproteinases and basement membrane remodeling. Hence keratinocyte dysfunction may be implicated in detachment of melanocytes from the basement membrane and subsequent loss from the epidermis, also potentially interfering with repigmentation in patients with stable disease. Furthermore, keratinocytes contribute to the autoimmune insult in vitiligo. Keratinocytes express MHC II in perilesional skin and may present melanosomal antigens in the context of MHC class II after the pigmented organelles have been transferred from melanocytes. Moreover, keratinocytes secrete cytokines and chemokines including CXCL-9, CXCL-10, and IL-15 that amplify the inflammatory circuit within vitiligo skin and recruit melanocyte-specific, skin-resident memory T cells. In summary, keratinocytes can influence vitiligo development by a combination of failing to produce survival factors, limiting melanocyte adhesion in lesional skin, presenting melanocyte antigens and enhancing the recruitment of pathogenic T cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.